Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine +

Decibel Reports First Quarter 2026 Results: Quarterly Revenue Grows 41% YoY to $30 Million, Issues Q2 2026 Guidance

Decibel Cannabis Confirms Turnaround Trajectory with Q1 Revenue Surge, Yet FCF Drag Lingers

Executive Summary
  • Decibel reported First Quarter 2026 net revenue of $30 million, a 41% year-over-year increase.
  • International sales surged 330% YoY to $9.6 million, while domestic sales grew 7% to $20.3 million.
  • Adjusted EBITDA doubled YoY to $6.9 million; adjusted net income turned profitable at $3.1 million versus a loss in Q1 2025.
  • Free Cash Flow was negative ($14.6 million) due primarily to a one-time $13.2 million reduction in payables settled via debt refinancing.
  • Company issued Q2 2026 revenue guidance of $33 million to $35 million and reaffirmed full-year 2026 guidance ($130M-$135M Revenue, $27M-$31M EBITDA).
  • Germany shipments completed in Q1; management expects growth as permit processing improves.
  • Creston property sale agreement remains conditional with expected completion before June 30, 2026, saving $4 million annually.
Material Impact
  • The earnings results confirm the trajectory established in the April 2026 full-year guidance release; revenue and EBITDA growth are consistent with expectations rather than surprising upside.
  • International sales tripling (330%) validates the AgMedica integration strategy but does not constitute a new strategic shift, as this was anticipated following the February debt refinancing.
  • The reaffirmation of full-year guidance after previous cuts in November 2025 reduces execution risk but is largely priced into the stock given the April announcement.
  • Free Cash Flow negative reading is explained by a non-recurring working capital adjustment ($13.2M payable settlement), masking underlying operational cash generation which was positive in prior quarters (e.g., Q4 2025 FCF $3 million).
  • The debt refinancing closed in February extends maturities to 2030, removing near-term solvency risk but increasing leverage on the balance sheet.
  • Overall impact is positive for operational stability but lacks the "unexpected" element required for a Material - Game Changer or Material - Positive rating under strict definitions.
DB · Price
Company Overview
  • Decibel Cannabis Company Inc. operates as a vertically integrated cannabis producer with a focus on ready-to-consume products and international export.
  • Flagship Project: AgMedica Bioscience integration for international GMP-extracted product supply, specifically targeting Germany and other regulated markets.
  • Domestic Portfolio: Brands include General Admission (Liquid Diamond 510) and Standard Issue (Vape/Pre-Roll).
  • Processing Capacity: 60 tons per annum flower processing capacity at ~30% utilization; consolidation planned with Battleford facility.
  • Market Position: Canadian recreational market share grew from 4.1% to 4.4%; International sales now represent significant growth driver (330% YoY).
Read the original news release →

More from Decibel Cannabis Company Inc.